Obstetrics & Gynecology 2013-02-01

Management of uterine bleeding during hematopoietic stem cell transplantation.

Stephanie E Purisch, Dana Shanis, Christa Zerbe, Melissa Merideth, Jennifer Cuellar-Rodriguez, Pamela Stratton

Index: Obstet. Gynecol. 121(2 Pt 2 Suppl 1) , 424-7, (2013)

Full Text: HTML

Abstract

Hematopoietic stem cell transplant is an effective treatment strategy for a variety of hematologic disorders, but patients are at risk for dysfunctional coagulation and abnormal bleeding. Gynecologists are often consulted before transplant for management of abnormal uterine bleeding, which may be particularly challenging in this context.A premenopausal woman with MonoMAC (a rare adult-onset immunodeficiency syndrome characterized by monocytopenia and Mycobacterium avium complex infections resulting from mutations in GATA2, a crucial gene in early hematopoiesis) presented with pancytopenia, evolving leukemia, and recent strokes, necessitating anticoagulation. During preparation for hematopoietic stem cell transplant, she experienced prolonged menorrhagia requiring transfusions. Surgical therapy was contraindicated, and medical management was successful only when combined with balloon tamponade.Balloon tamponade may be a potentially life-saving adjunct to medical therapy for control of uterine hemorrhage before hematopoietic stem cell transplant.

Related Compounds

Structure Name/CAS No. Articles
Leuprolide TFA Structure Leuprolide TFA
CAS:53714-56-0
medroxyprogesterone Structure medroxyprogesterone
CAS:520-85-4
(Des-Gly10,D-Leu6,Pro-NHEt9)-LHRH acetate salt Structure (Des-Gly10,D-Leu6,Pro-NHEt9)-LHRH acetate salt
CAS:74381-53-6